Bicycle Therapeutics (BCYC) Gains from Investment Securities (2018 - 2019)
Bicycle Therapeutics' (BCYC) quarterly Gains from Investment Securities came in at -$19000.0 in Q4 2019, up 97.65% YoY from -$9613.2 in Q4 2018, and down 100.86% on a QoQ basis from $2.2 million in Q2 2019.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Gains from Investment Securities (2018 - 2019) Analysis & Trends
Bicycle Therapeutics (BCYC) has 2 years of Gains from Investment Securities data on file, last reported at -$19000.0 in Q4 2019.
- Quarterly Gains from Investment Securities rose 97.65% year-over-year to -$19000.0 in Q4 2019, while the trailing twelve-month figure through Sep 2020 was -$19000.0 (down 100.41% YoY) and the FY2019 annual result came in at $5.4 million, up 709.17% from the prior year.
- Gains from Investment Securities eased to -$19000.0 in Q4 2019, from $2.2 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $3.2 million in Q1 2019 to a low of -$807000.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -19,000.00 |
| Jun 30, 2019 | 2.20 Mn |
| Mar 31, 2019 | 3.20 Mn |
| Dec 31, 2018 | -807,000.00 |
| Sep 30, 2018 | 1.36 Mn |